Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome

• Published in: Biology of blood and marrow transplantation Vol. 9; no. 11; pp. 698 - 705
• Main Authors: Hale, G.A, Rochester, R.J, Heslop, H.E, Krance, R.A, Gingrich, J.R, Benaim, E, Horwitz, E.M, Cunningham, J.M, Tong, X, Srivastava, D.K, Leung, W.H, Woodard, P, Bowman, L.C, Handgretinger, R
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2003
• Subjects: Acute Disease; Adenovirus; Adolescent; Adult; Bone marrow transplantation; Bone Marrow Transplantation - adverse effects; Child; Child, Preschool; Chronic Disease; Complications; Cystitis - etiology; Family; Graft vs Host Disease - epidemiology; Graft vs Host Disease - prevention & control; Hemorrhagic cystitis; Hemorrhagic Disorders - epidemiology; Hemorrhagic Disorders - etiology; Humans; Infant; Living Donors; Lymphocyte Transfusion; Middle Aged; Neoplasms - drug therapy; Pediatrics; Retrospective Studies; Risk Factors; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Bone marrow transplantation; Pediatrics; Adenovirus; Complications; Hemorrhagic cystitis
• ISSN: 1083-8791; 1523-6536
• DOI: 10.1016/S1083-8791(03)00269-6

Hemorrhagic cystitis (HC) is a well-documented adverse event experienced by patients undergoing hematopoietic stem cell transplantation. When severe, HC causes significant morbidity, leads to renal complications, prolongs hospitalization, increases health-care costs, and occasionally contributes to death. We retrospectively studied the medical records of 245 children undergoing an initial allogeneic bone marrow transplantation for malignant disease at St. Jude Children’s Research Hospital between 1992 and 1999 to describe the clinical course of HC in all patients and to identify the risk factors for HC in this cohort. Conditioning regimens included cyclophosphamide, cytarabine, and total body irradiation. Grafts from unrelated or mismatched related donors were depleted of T lymphocytes, whereas matched sibling grafts were unmanipulated. All patients received cyclosporine as prophylaxis for graft-versus-host disease. Recipients of grafts from matched siblings also received pentoxifylline or short-course methotrexate. Severe HC developed in 27 patients (11.0%). The median duration of HC was 73 days (range, 5–619 days); 12 patients had ongoing HC at the time of death. In univariate analyses, patients were at increased risk of severe HC if they were male ( P = .021) or had received T cell-depleted grafts ( P = .017), grafts from unrelated donors ( P = .021), a lower total nucleated cell dose ( P = .032), or antithymocyte globulin ( P = .0446). Multiple regression analysis revealed male sex (β = .97; P = .027) and unrelated donor graft recipients (β = .83; P = .039) to be significant factors.